![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Induction Healthcare Group Plc | LSE:INHC | London | Ordinary Share | GB00BJ0M3545 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.00 | 9.00 | 11.00 | 10.00 | 10.00 | 10.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 12.88M | -17.38M | -0.1882 | -0.53 | 9.24M |
TIDMINHC
RNS Number : 5227I
Induction Healthcare Group PLC
05 December 2022
Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Unaudited Interim Results
for the six months ended 30 September 2022
Induction Healthcare (AIM: INHC), a leading digital health platform driving transformation of healthcare systems , announces its unaudited interim results for the six months ended 30 September 2022, a period of continued revenue growth driven by the Company's leading position providing products to support the digitization of healthcare delivery.
Induction's products power remote consultations, capture patient reported data and empower patients to self-manage their care pathway. They are designed around the needs of the patient and deliver cost and efficiency benefits to hospitals, regional care systems and governments. Used at scale by national and regional healthcare systems, Induction's applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
Financial Highlights
-- Recorded Revenues up 54% to GBP7.1m (H1 2021: GBP4.6m) with organic growth across key products
- Induction Attend Anywhere revenues GBP5.6m (H1 2021: GBP3.6m) - Induction Zesty revenue GBP1.1m (H1 2021: GBP0.6m) -- Adjusted EBITDA loss of GBP1.0m (H1 2021: GBP0.7m)
-- Annual Recurring Revenues ("ARR") at period end of GBP14.5m up from GBP13.5m at the start of H1 2022
-- Cash position as at 30 September 2022 of GBP9.0m (31 March 2022: GBP7.5m)
Operational Highlights
-- Strong start to the financial year with better-than-expected Induction Attend Anywhere renewals across NHS England
-- Value Added Reseller agreement signed with System C for Induction Zesty
-- Induction Zesty contracts with 8 further hospitals in England, building on the previously announced contract win with 4 hospitals in South West London
-- Christopher Samler appointed as Non-Executive Chairman
James Balmain, CEO of Induction, said: " We are confident that the business is well-positioned to deliver continued revenue growth from its core products, Induction Attend Anywhere and Induction Zesty. It is however apparent that the rate of growth this year will be impacted by the delays we've seen in the implementation of centrally funded digitisation programmes and the general political turmoil of recent months. We don't expect to see these opportunities drop away, rather they are now more likely to conclude next financial year.
"Despite these headwinds, we remain confident that overall year end revenues will show an improvement of at least 75% against our year end 31 March 2022 recognised revenues of GBP7.9m and we expect to grow our recurring revenues by at least 23% year on year. Both of these key metrics, whilst encouraging, are lower than our expectation and as a result the business is heavily focussed on underlying profitability and cash. We have initiated programmes internally to ensure our business is sized correctly to capture growth and to ensure that we do not have to raise further working capital pending reaching our objective of cash-flow breakeven by the fourth quarter of next financial year.
"Nothing has changed in terms of the critical need to further advance the digital transformation of the NHS, and in particular to drive efficiencies and support the reduction of extended waiting times. The strategic pillars for growth, as described in our recently published Annual Report remain as relevant as before and we remain confident about the future prospects of the Group."
Investor Presentation
The Company will be hosting a live online presentation via the Investor Meet Company platform at 4pm (GMT) today. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/induction-healthcare-group-plc/register-investor .
A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform and the Company's investor website afterwards.
ENQUIRIES
Induction Via Walbrook PR Ltd: induction@walbrookpr.com James Balmain, Chief Executive Officer Christopher Samler, Chair Singer Capital Markets (Nominated Adviser and Broker) +44 (0)20 7496 3000 Philip Davies / Kailey Aliyar Walbrook PR Ltd induction@walbrookpr.com Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
CEO REVIEW
Overview
Over the last six months we have seen continued year-on-year revenue growth from our Induction Zesty patient engagement platform and maintained strong annually recurring revenue from our Induction Attend Anywhere video consultation platform, building on a successful renewal of key NHS England contracts at the start of the year.
The need to continue the digital transformation of the NHS remains as strong as ever. Despite recent political and economic turmoil in the UK, delivering this transformation is still very much a key focus for the Government and NHS bodies across the UK. There is committed funding to support the roll-out of software that will help reduce NHS waiting lists.
However, the allocation of this central capital to fund key digital programmes has been slower than expected. Central funding and policy guidance is now in place to drive all hospitals in England to have suitable patient engagement platforms in place by the end of March 2023 . This has had the net effect of deferring some expected contract wins and their associated revenue into next financial year.
Induction is well positioned to receive new contracts as a result of this funding:
-- Induction Attend Anywhere is the leading hospital video consultation platform throughout NHS England
-- Induction Zesty's selected as one of the first four patient engagement platforms to be directly integrated into the NHS App
-- To qualify for central funding NHS Trusts have been strongly encouraged to procure those platforms that have integrated into the NHS App
-- Induction's unique Value Added Reseller Agreements with both Oracle Cerner and System C for Induction Zesty allows Induction to exclusively capture separate funding made available for upgrades to hospital EMR systems.
H1 performance
Overall recorded revenues for the first half showed an improvement of just over 54% to GBP7.1m (H1 2021: GBP4.6m).
We continue to work closely with NHS Wales, NHS Scotland and the Scottish government in ensuring Induction Attend Anywhere continues to deliver a high quality service to the millions of users it serves. Looking ahead to the second half of this year, we remain confident in key H2 contract renewals with these customers.
We have seen some delays in the roll-out of Induction Attend Anywhere in relation to the Department of Work and Pensions (DWP) contract announced in November 2021 as we seek to meet changing platform requirements from the DWP. Completion of these platform updates will be required before the DWP can make the platform available to a wider range of departments, a key driver of increased revenue.
As announced in April, the South West London ICS, comprising four NHS Acute Trusts, signed up to deploy Induction Zesty to support their outpatient transformation programme. Building on this, eight further hospitals have been signed as at 30 September. Induction Zesty revenues nearly doubled to GBP1.1m (H1 2021: GBP0.6m) and, for the reasons described above, we believe we will see further significant sales growth in Induction Zesty sales in the second half and through into the next financial year, albeit at a slower rate than originally anticipated.
Other Induction products (our clinical apps Induction Guidance and Induction Switch) delivered revenues of GBP0.4m (H1 2021: GBP0.3m). As we've stated in our Annual Report, given the relatively minor contribution of these clinical apps to overall group revenues, as well as their cost base, we are considering the future role of clinical apps within the group.
At the period end, the Group recorded GBP14.5m of annual recurring revenue (compared to GBP13.5m at the start of H1 2022) with recurring revenue for the period accounting for over 90% of total revenues.
In the first half we recorded an adjusted EBITDA loss of GBP1.0m (H1 2021: GBP0.7m).
Cash position
The Group ended the first half with cash on hand of GBP9.0 m ( 31 March 2022: GBP7.5m).
We currently expect revenue for the full year to be approximately GBP3m lower than forecast . In addition, we expect cost escalations of GBP0.9m relating to increased hosting costs (AWS) and adverse foreign exchange movements versus the US Dollar which is the payment currency of many of our IT services. To offset this , the business is con ducting an immediate review of its expenditure to align with the current and expected future growth of our public sector customer base. These and other related savings will be material and are to be initiated forthwith, although the benefits are not expected to fully flow through until the first half of next financial year.
The majority, by value, of our main Induction Attend Anywhere contracts renew at the end of March . We therefore receive significant cash inflows during April and May. A notable feature of the recent upheaval across public sector finance is a move towards fewer advance payments and a trend towards quarterly payments . These two trends further underline the need to tightly manage our expenditure, enforce our contractual payment terms more rigorously and drive the business towards profitability. The Group considers that it should give more prominence to adjusted operating income (free cash flow) which will provide investors with a clearer view of cash generation from operations.
Whilst we currently do not foresee a need for further working capital, it is not yet possible to fully quantify the value and timing of our major contracts or the cadence of their cash inflows. T he Group intends to update its guidance on this metric , providing investors with additional clarity in due course. In the meantime, we recognise the need to take a conservative approach to cash and cash management.
Board Changes
During the first half we announced a number of Board changes as part of the natural evolution of the business. In May 2022 Dr Hugo Stephenson returned to the Non-executive Director role he originally held on admission to AIM in May 2019, and in July 2022 we announced the appointment of Christopher Samler as Non-Executive Chairman and the executive team are delighted to benefit from their combined experience and support as we drive the business forward.
Ian Johnson has been appointed to the Board as the Senior Independent Director ('SID') replacing Leslie-Ann Reed who will be stepping down following completion of her three-year term. Ian brings over 30 years of Board experience working with quoted and private companies in the Life Sciences space, having spent a career providing strategic direction and business development expertise. He has a proven track record of overseeing business growth and providing commercial advice through scale-up, organic growth and M&A activity.
More recently, Guy Mitchell has stepped down as the company CFO and is replaced by John Mcintosh as Interim CFO. The board will commence a process to recruit a permanent CFO.
James Balmain
Chief Executive Officer
Condensed Income Statement (Unaudited)
For the six months ended 30 September 2022
30 September 2022 30 September 2021 Unaudited Unaudited Note GBP'000 GBP'000 ------------------ ------------------ Revenue from contracts with customers 2 7,118 4,593 Cost of sales (2,414) (997) --------------------------------------- ------------------ ------------------ Gross Profit 4,704 3,596 Sales and marketing expenses 3 (821) (514) Development expenses 3 (4,159) (2,711) Administrative expenses 3 (4,237) (5,959) Operating loss (4,513) (5,588) --------------------------------------- ------------------ ------------------ Finance Costs (4) (12) Finance Income - - --------------------------------------- ----- ------------------ ------------------ Loss before tax (4,517) (5,600) --------------------------------------- ------------------ ------------------ Taxation (311) (404) --------------------------------------- Loss for the financial period (4,828) (6,004) --------------------------------------- ------------------ ------------------ Attributable to: Equity holders of the parent (4,828) (6,004) --------------------------------------- (4,828) (6,004) --------------------------------------- ------------------ ------------------ Loss per share from operations --------------------------------------- ------------------ ------------------ - Basic 4 (0.06) (0.08) - Diluted 4 (0.06) (0.08) --------------------------------------- ------------------ ------------------
Condensed Consolidated Statement of Comprehensive Income (Unaudited)
For the six months ended 30 September 2022
30 September 30 September 2022 2021 Unaudited Unaudited Note GBP'000 GBP'000 ------------- ------------- Loss for the period (4,828) (6,004) -------------------------------- ------------- ------------- Other comprehensive income Items that may be reclassified to profit or loss Foreign currency translation differences 457 (59) Reclassified to profit and loss during the period (801) 9 Other comprehensive income for the financial period (344) 50 -------------------------------- ------------- ------------- Total comprehensive loss for the financial period (5,172) (6,054) -------------------------------- ------------- ------------- Attributable to: Equity holders of the parent (5,172) (6,054) (5,172) (6,054) -------------------------------- ------------- ------------- Loss per share: Basic loss per share (GBP) 4 (0.06) (0.08) Diluted loss per share (GBP) 4 (0.06) (0.08)
Unaudited Condensed Consolidated Statement of Financial Position
As at 30 September 2022
30 September 31 March 2022 2022 Unaudited Unaudited Note GBP'000 GBP'000 ------------- ---------- Non-current assets Goodwill 6 19,758 19,758 Intangible Assets 6 20,213 20,962 Property, Plant and Equipment 213 244 Deferred tax assets 1,549 1,540 41,733 42,504 ----------------------------------------------------- ------------- ---------- Current assets Trade and other receivables 7 3,543 3,349 Contract Assets 2 2,090 787 Current tax receivable 1,208 1,240 Cash and cash equivalents 7 8,978 7,495 ----------------------------------------------------- 15,819 12,872 ----------------------------------------------------- ------------- ---------- Total assets 57,552 55,376 ----------------------------------------------------- ------------- ---------- Non-current liabilities Contract liabilities 2 (310) (326) Deferred tax liabilities 2 (5,833) (5,851) Other financial liabilities 2 (170) (128) (6,313) (6,305) ----------------------------------------------------- ------------- ---------- Current liabilities Trade and other payables 8 (4,316) (3,365) Contract liabilities (8,944) (2,580) Current tax payable (833) (789) Other financial liabilities - (73) (14,093) (6,806)
----------------------------------------------------- ------------- ---------- Total liabilities (20,406) (13,111) ----------------------------------------------------- Net assets/(liabilities) 37,146 42,265 ----------------------------------------------------- ------------- ---------- Equity attributable to equity holders of the parent Share capital 9 471 460 Share premium 9 41,665 41,665 Translation reserve 9 457 801 Other reserves 9 1,447 1,405 Merger reserve 9 20,206 20,206 Accumulated deficit (27,100) (22,272) ----------------------------------------------------- Total equity 37,146 42,265 ----------------------------------------------------- ------------- ----------
Unaudited Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 September 2022
Share Share Translation Other Merger Accumulated Total Capital Premium reserve reserve reserve deficit equity GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 ---------------- ----------------- -------------- -------------------- -------------------- -------------- ------------------- ----------- Balance at 1 April 2022 460 41,665 801 1,405 20,206 (22,272) 42,265 Total comprehensive loss for the period Loss for the period - - - - - (4,828) (4,828) Other comprehensive loss for the period - - (344) - - - (344) Total comprehensive loss for the period - - (344) - - (4,828) (5,172) ---------------- ----------------- -------------- -------------------- -------------------- -------------- ------------------- ----------- Transactions with owners, in their capacity as owners Issue of ordinary shares 11 - - (204) - - (193) Issue of ordinary shares as consideration for a business combination - - - - - - - Equity-settled share-based payments - - - 246 - - 246 Total contributions by and distributions to owners 11 - - 42 - - 53 ---------------- ----------------- -------------- -------------------- -------------------- -------------- ------------------- ----------- Balance at 30 September 2022 471 41,665 457 1,447 20,206 (27,100) 37,146 ---------------- ----------------- -------------- -------------------- -------------------- -------------- ------------------- -----------
Unaudited Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 September 2022
Share Share Translation Other Merger Accumulated Total Capital Premium reserve reserve reserve deficit equity GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 ---------------- ------------------ -------------- ------------------- -------------------- ------------------ ------------------- ----------- Balance at 1 April 2021 210 18,432 (9) 792 10,879 (13,838) 16,466 Total comprehensive loss for the period Loss for the period - - - - - (6,004) (6,004) Other comprehensive loss for the period - - (50) - - - 37 Total comprehensive loss for the period - - (50) - - (6,004) (6,004) ---------------- ------------------ -------------- ------------------- -------------------- ------------------ ------------------- ----------- Transactions with owners, in their capacity as owners Issue of ordinary shares 179 24,821 - - - - 25,000 Issue of ordinary shares as consideration for a business combination 71 - - - 8,928 - 9,000 Equity-settled share-based payments - - - 332 - - 332 Total contributions by and distributions to owners 250 28,821 - 332 8,928 - 34,332 ---------------- ------------------ -------------- ------------------- -------------------- ------------------ ------------------- ----------- Balance at 30 September 2021 460 43,253 (59) 1,124 19,807 (19,842) 44,747 ---------------- ------------------ -------------- ------------------- -------------------- ------------------ ------------------- -----------
Unaudited Condensed Consolidated Statement of Cash Flows
For the six months ended 30 September 2022
For the period ended For the period ended 30 September 2022 30 September 2021 GBP'000 GBP'000 ------------------------------------------------------------------- --------------------- --------------------- Cash flows from operating activities Loss for the financial period (4,828) (6,004) Adjustments for: Depreciation of property, plant and equipment 39 4 Amortisation and impairment of intangible assets 2,363 1,569 Finance costs 4 12 Finance income - - Share-based payment expense 246 332 Net foreign exchange differences - 49 Fair value adjustment of contingent consideration - - Net loss arising on fair value adjustments of deferred income - 1,742 Taxation 311 404 2,963 4,112 --------------------- --------------------- Decrease / (Increase) in trade and other receivables and contract assets (1,500) 3,911 (Decrease) / Increase in trade and other payables and contract liabilities 7,303 (1,491) Interest received - - Interest paid (4) (12) Income taxes received 44 - Income taxes paid (288) (404) Net cash generated from / (used in) operating activities 3,690 112 -------------------------------------------------------------------- --------------------- ---------------------
Cash flows from investing activities Payments for acquiring businesses, net of cash acquired - (13,486) Payment of software development costs (1,615) (1,207) Acquisitions of property, plant and equipment (5) - Net cash from investing activities (1,620) (14,693) -------------------------------------------------------------------- --------------------- --------------------- Cash flow from financial activities Repayments of loans and borrowings - - Share issue costs - - Share issue proceeds (194) 25,000 Net cash from financing activities (194) 25,000 -------------------------------------------------------------------- --------------------- --------------------- Net increase in cash equivalents 1,876 10,419 Cash and cash equivalents at the beginning of the financial period 7,495 2,472 Effects of exchange rate changes on cash and cash equivalents (393) (49) Cash and cash equivalents at the end of the financial period 8,978 12,842 ==================================================================== ===================== =====================
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
1. Accounting Policies
1.1 Reporting entity
Induction Healthcare Group PLC ("Induction", the "Group" or the "Company") is publicly listed on the AIM market of the London Stock Exchange ("LSE"), and incorporated, domiciled and registered in the United Kingdom. The registered number is 11852026 and the registered address is 20 St. Dunstan's Hill, London, United Kingdom, EC3R 8HL. Induction is a leading healthcare technology company helping to streamline delivery of care by providing software to healthcare professionals.
As of 30 September 2022, Induction Healthcare Group PLC comprised of nine legal subsidiaries, that are majority owned and controlled, and therefore fully consolidated in the Company's consolidated financial statements. Details of the Company's subsidiaries are included in note 5.
1.2 Basis of preparation
These interim financial statements have been prepared and approved by the directors in accordance with International Financial Reporting Standards ("Adopted IFRSs"). They do not include all the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the most recent annual consolidated financial information included in the annual report and accounts as of and for the year ended 31 March 2022.
The accounting policies applied are consistent with those applied in the most recent consolidated annual report and accounts for the year ended 31 March 2022, which are available on the Company's website at www.inductionhealthcare.com under "Investors - Financial reports & publications."
Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtained control and continue to be consolidated until the date when such control ceases. The financial information of the subsidiaries is prepared for the same reporting period as the Group, using consistent accounting policies. All intra-group balances, transactions, unrealised gains and losses resulting from intra-group transactions are eliminated in full.
Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.
When the Group loses control over a subsidiary, the assets and liabilities are derecognised along with any related non-controlling interest and other components of equity. Any resulting gain or loss is recognised in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.
These interim condensed consolidated financial statements are unaudited and were approved by the Board of Directors and authorised for issue on 5 December 2022 and are available on the Company's website at www.inductionhealthcare.com under "Investors - Financial reports & publications".
2. Revenue
2.1 Revenue by performance obligations
Period to 30 September 2022 Period to 30 September 2021 GBP'000 GBP'000 --------------------------------------------- ---------------------------- ----------------------- Provision of software 6,296 4,382 Post-contract support and maintenance 103 76 Set-up services 30 3 Professional services 492 - Text message revenue 197 132 ---------------------------------------------- Total Revenue from contracts with customers 7,118 4,593 ---------------------------------------------- ---------------------------- -----------------------
2.2 Revenue by geographical location
Period to 30 September Period to 30 September 2022 2021 GBP'000 GBP'000 --------------------------------------------- ----------------------- ----------------------- United Kingdom 7,086 4,528 Europe 7 6 United States 9 8 Rest of World 16 51 ---------------------------------------------- ----------------------- ----------------------- Total Revenue from contracts with customers 7,118 4,593 ---------------------------------------------- ----------------------- -----------------------
2.3 Revenue by product line
Period to 30 September Period to 30 September 2022 2021 GBP'000 GBP'000 --------------------------------------------- ----------------------- ----------------------- Induction Anywhere 5,600 3,638 Induction Zesty 1,162 617 Induction Guidance 340 322 Induction Switch 16 16 ---------------------------------------------- ----------------------- ----------------------- Total Revenue from contracts with customers 7,118 4,593 ---------------------------------------------- ----------------------- -----------------------
2.4 Timing of revenue recognition
Period to 30 September Period to 30 September 2022 2021 GBP'000 GBP'000 --------------------------------------------- ----------------------- ----------------------- Services transferred over time 6,628 4,451 Services transferred at a point in time 490 142 Total Revenue from contracts with customers 7,118 4,593 ---------------------------------------------- ----------------------- -----------------------
2.5 Contract balances
31 March 30 September 2022 2022 GBP'000 GBP'000 ---------------------- ------------------ --------- Trade receivables 2,121 1,039 Contract assets 2,090 399 Contract liabilities (9,254) (2,657)
3. Expenses by nature
Period to 30 September Period to 30 September 2022 2021 GBP'000 GBP'000 ---------------------- ---------------------- Employee benefit expense 4,810 3,444 Contractors 1,858 1,520 Fundraise and acquisition related transaction costs - 1,613 Amortisation of intangible assets 2,363 1,568 Depreciation of property, plant and equipment 39 4 Professional and legal fees 251 56 Research and development expense capitalised (1,615) (1,207) Remeasurement of contingent consideration - - Fair value adjustments on contract liabilities - 1,742
4. Earnings per share
Basic EPS is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.
Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent (after adjusting for interest on the convertible preference shares) by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.
The following table reflects the income and share data used in the basic and diluted EPS calculations:
Loss attributable to ordinary shares (basic and diluted)
30 September 30 September 2022 2021 GBP'000 GBP'000 --------------------------------------------------------- ------------ ------------ Loss attributable to ordinary shares (basic and diluted) (4,828) (6,004) ---------------------------------------------------------- ------------ ------------ (4,828) (6,004) ------------ ------------
Weighted average number of ordinary shares (basic and diluted)
Period to 30 September 2022 Period to 30 September 2021 ----------------------------------------------------- ---------------------------- ---------------------------- Shares in issue on 1 April 92,050,727 42,050,728 Shares issued 248,089 35,714,285 Shares issued in a business combination - 14,285,714 ------------------------------------------------------ Issued ordinary shares as at the end of the period 92,298,816 92,050,727 ------------------------------------------------------ ---------------------------- ---------------------------- Weighted-average number of ordinary shares (basic and diluted) 73,413,131 72,925,044 ------------------------------------------------------ ---------------------------- ---------------------------- Basic loss per share (0.06) (0.08) Diluted loss per share (0.06) (0.08)
5. Investments in subsidiaries
Company Registered number Principal Country of Ownership activities incorporation -------------------- ------------------ ------------------- ------------------- 30 September 2022 31 March 2022 -------------------- ------------------ ------------------- ------------------- ------------------ -------------- Induction Investment Holding Healthcare Limited 11232772 Company United Kingdom 100% 100% Induction 11237890 Provision of United Kingdom 100% 100% Healthcare (UK) software to Limited healthcare providers Induction 625119397 Provision of Australia 100% 100% Healthcare Pty Ltd software to healthcare providers Podmedics Limited 6840040 Dormant United Kingdom 100% 100% Horizon Strategic 6285278 Provision of United Kingdom 100% 100% Partners Limited software to healthcare providers Zesty Limited 08294659 Provision of United Kingdom 100% 100% software to healthcare providers Attend Anywhere Pty 081211707 Provision of Australia 100% 100% Ltd software to healthcare providers Attend Anywhere 11883931 Provision of United Kingdom 100% 100% Limited software to healthcare providers A.C.N. 167 231 307 Investment Holding Pty Ltd 167231307 Company Australia 100% 100%
6. Goodwill and intangible assets
Goodwill Technology Users Tradename Development costs Total GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 ---------------------------- --------- ----------- -------- ---------- ------------------ -------- Cost Balance at 31 March 2022 20,175 7,972 9,460 633 9,442 47,682 Recognised on acquisitions - - - - - - Internally developed - - - - 1,615 1,615 Translation differences - - - - - - At 30 September 2022 20,175 7,972 9,460 633 11,057 49,297 ---------------------------- --------- ----------- -------- ---------- ------------------ -------- Amortisation Balance at 31 March 2022 418 1,532 1,386 144 3,482 6,962 Recognised on acquisitions - - - - - - Provided during the year - 719 645 31 968 2,363 Translation differences - - - - - - At 30 September 2022 418 2,251 2,031 175 4,450 9,325 ---------------------------- ------- ------ ------ ---- ------ ------- Net book value At 31 March 2022 19,757 6,440 8,074 489 5,960 40,720 ---------------------------- ------- ------ ------ ---- ------ ------- At 30 September 2022 19,757 5,721 7,429 458 6,607 39,972 ---------------------------- ------- ------ ------ ---- ------ -------
7. Trade and other receivables
30 September 2022 31 March 2022 GBP'000 GBP'000 Receivables from third-party customers 2,880 2,900 Other receivables 210 116 Prepayments 373 251 Social security and other taxes receivable 80 82 ------------------ --------- 3,543 3,349 ------------------ --------- Allowance for credit losses - - ------------------ --------- 3,543 3,349 ------------------ ---------
Trade receivables are non-interest bearing and are generally on terms of 30 days. Included within trade and other receivables is GBPnil expected to be recovered in more than 12 months.
Cash and cash equivalents
30 September 2021 31 March 2022 GBP'000 GBP'000 Cash at banks and on hand 8,978 6,995 Short-term deposits - 500 ------------------ ------------------ Cash and cash equivalents per the statement of financial position and cash flow statement 8,978 7,495 ------------------ ------------------
Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made on a weekly basis, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates.
8. Trade and other payables
30 September 31 March 2022 2022 GBP'000 GBP'000 ------------- -------------- Trade payables 833 901 Accruals 1,864 1,680 Social security and other taxes 230 238 Other payables 1,389 108 Current tax payable 833 765 ------------- -------------- 5,149 3,692 ------------- --------------
Included within trade and other payables is GBPnil expected to be settled in more than 12 months.
All trade and other payables are non-interest bearing and are normally settled on 30 day terms.
9. Capital and Reserves
9.1 Share Capital
2022 2021 No. of shares ('000) GBP'000 No. of shares ('000) GBP'000 --------------------- -------- --------------------- -------- In issue at 1 April 92,051 460 42,051 210 Issue of ordinary shares as consideration for a business combination - - 14,286 71 Issue of ordinary shares 248 1 35,714 179 --------------------- -------- --------------------- -------- In issue at 30 September 92,299 461 92,051 460 --------------------- -------- --------------------- --------
9.2 Share Premium
2022 2021 GBP'000 GBP'000 (Restated) -------- ----------- At 1 April 41,665 18,432 Issue of ordinary shares as consideration for a business combination - 23,223 At 30 September 41,665 41,665 -------- -----------
9.3 Merger Reserve
2022 2021 GBP'000 GBP'000 (Restated) At 1 April 2022 20,206 10,879 Issue of ordinary shares as consideration for a business combination - 9,327 Transaction costs on issue of shares - - At 30 September 2022 20,206 20,206 -------- -----------
During the completion of the annual report and accounts for 31 March 2022, amounts recognised in share premium that related to the issuance of ordinary shares as consideration for a business combination were reclassified to the merger reserve. Management have therefore restated the amounts presented for the merger reserve and for the share premium for the 6 months ended 30 September 2021 to reflect this.
10. Related Parties
Transactions with key management personnel
The compensation of key management personnel (directors) is as follows:
30 September 2022 30 September 2021 GBP'000 GBP'000 ------------------ ------------------ Short-term employee benefits 338 384 Post-employment pension and other benefits 8 6 Termination benefits - - Share based payment transactions 123 123 Key management remuneration including social security costs 469 513 ------------------ ------------------ Total compensation paid to key management personnel 469 513 ------------------ ------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR DDBDDIBGDGDS
(END) Dow Jones Newswires
December 05, 2022 02:00 ET (07:00 GMT)
1 Year Induction Healthcare Chart |
1 Month Induction Healthcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions